Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of intravesical VPM1002BC in recurrent non-muscle invasive bladder cancer after standard BCG therapy
2014-005330-58Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant BCG in bladder cancer, sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Phase II primary endpoint. Started Mar 2016; status: completed.
02
Drugs
recombinant BCG
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2014-005330-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005330-58.